financetom
Business
financetom
/
Business
/
Update: Texas Instruments Q2 Earnings, Sales Rise But Earnings Call Fails to Inspire Wall Street; Shares Slump Premarket
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Texas Instruments Q2 Earnings, Sales Rise But Earnings Call Fails to Inspire Wall Street; Shares Slump Premarket
Jul 23, 2025 3:08 AM

05:52 AM EDT, 07/23/2025 (MT Newswires) -- (Updates with the stock move and analyst comments in the headline and the last four paragraphs.)

Texas Instruments ( TXN ) reported Q2 earnings late Tuesday of $1.41 per diluted share, up from $1.22 a year earlier.

Analysts polled by FactSet expected $1.36.

Revenue for the quarter ended June 30 was $4.45 billion, up from $3.82 billion a year earlier.

Analysts surveyed by FactSet expected $4.36 billion.

The company set Q3 EPS guidance of $1.36 to $1.60 on revenue of $4.45 billion to $4.80 billion. Analysts expected EPS of $1.51 on revenue of $4.59 billion.

Shares of Texas Instruments ( TXN ) were, however, down nearly 12% in recent premarket activity on Wednesday.

Cantor Fitzgerald's Matthew Prisco termed the management's tone on the earnings call as "definitively more cautious than 50 days ago," when Texas Instruments ( TXN ) executives discussed expectations for accelerating quarterly revenue growth this year, according to a news report from Dow Jones published by Morningstar.

That earlier talk implied higher third-quarter revenue than the midpoint of Texas Instruments' ( TXN ) latest guidance, by Prisco's math, the news report said.

Bernstein analyst Stacy Rasgon was cited as saying that the company's "tone appears to have shifted markedly with seemingly more caution around the geopolitical and tariff environment, and an admission of probable tariff-related pull-forward now somewhat tempering the company's continued optimism around the cycle."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Paramount Global, Mediacom Renew Distribution Deals
Paramount Global, Mediacom Renew Distribution Deals
Jul 1, 2025
10:03 AM EDT, 07/01/2025 (MT Newswires) -- Paramount Global ( PARAA ) and Mediacom said Tuesday that they renewed their distribution agreements, extending Mediacom's carriage of Paramount's networks. No financial details were disclosed. Price: 12.95, Change: +0.05, Percent Change: +0.39 ...
What's Going On With Rocket Lab Stock On Tuesday?
What's Going On With Rocket Lab Stock On Tuesday?
Jul 1, 2025
Rocket Lab Corporation is trading higher in Tuesday’s premarket session following a major milestone in its national security business. The company announced it has successfully completed the Critical Design Review (CDR) for its 18-spacecraft mission under the U.S. Space Development Agency’s Tranche 2 Transport Layer-Beta (T2TL-Beta) program. According to Benzinga Pro, RKLB stock has gained over 687% in the past year....
Embraer Receives $4 Billion Aircraft Order From Scandinavian Airlines; Shares Up
Embraer Receives $4 Billion Aircraft Order From Scandinavian Airlines; Shares Up
Jul 1, 2025
10:02 AM EDT, 07/01/2025 (MT Newswires) -- Embraer ( ERJ ) shares were up more than 4% in early Tuesday trading after the company said it received an order from Scandinavian Airlines for 45 E195-E2 aircraft, with purchase rights for an additional 10 aircraft, valued at $4 billion excluding the purchase rights. The deliveries are scheduled to begin in late...
China's Innogen expects to complete weight-loss drug trials next year
China's Innogen expects to complete weight-loss drug trials next year
Jul 1, 2025
* Innogen's experimental drug approved for diabetes treatment * Innovent latest to secure China's approval for weight-loss drug * More weight-loss drugs seen coming onto the market, analyst says * Local competition in weight-loss drug market intensifying By Andrew Silver SHANGHAI, July 1 (Reuters) - Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug...
Copyright 2023-2025 - www.financetom.com All Rights Reserved